检查点抑制剂相关风湿性疾病的频率与分布
本文综述免疫检查点抑制剂(ICI)相关风湿性免疫不良事件(irAE)的流行病学数据。接受ICI治疗的患者中约5-10%可出现风湿性irAE,最常见为炎性关节炎、类风湿性多肌痛样综合征、肌炎和干燥症状;因缺乏前瞻性队列研究及肿瘤试验漏报,真实发生率尚无法确定。
要点
- ICI相关风湿性irAE约见于5-10%的ICI治疗患者。
- 最常见类型为炎性关节炎、多肌痛样综合征、肌炎和干燥表现。
- 缺乏前瞻性队列研究,真实发生率尚不能确定,且可能存在漏报。
核心结论
- 风湿性irAE在ICI治疗患者中约见于5-10%,但因缺乏前瞻性队列研究和肿瘤试验漏报,真实发生率无法估计。
研究设计与样本
- 本文为综述,汇总已报道的风湿性irAE流行病学数据,未报告检索范围与样本量。
主要发现
- 关节痛或肌痛等风湿症状非常常见,更特异的风湿性irAE报告日益增多。
- 最常见的风湿性irAE为炎性关节炎、多肌痛样综合征、肌炎和干燥表现。
- 风湿性irAE可发生于约5-10%的ICI治疗患者。
关键数值与推荐
- 原文未涉及诊断标准或推荐条款。
临床怎么用
- 原文未涉及临床处置推荐。
局限性
- 缺乏前瞻性队列研究,肿瘤试验中风湿性irAE可能漏报,真实发生率无法估计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immune checkpoint inhibitors have advanced the treatment paradigm of various cancers, achieving remarkable survival benefits. However, a myriad of immune-related adverse events (irAE) has been recognized in almost every organ system, presumably because of persistent immune system activation. Rheumatic symptoms such as arthralgia or myalgia are very common. More specific irAE are increasingly being reported. The most frequent ones are inflammatory arthritis, polymyalgia-like syndromes, myositis and sicca manifestations. These rheumatic irAE can develop in ∼5-10% of patients treated with immune checkpoint inhibitors, although true incidence rates cannot be estimated given the lack of prospective cohort studies, and likely underreporting of rheumatic irAE in oncology trials. In this review, we will provide a summary of the epidemiologic data reported for these rheumatic irAE, until more robust prospective longitudinal studies become available to further define the true incidence rate of rheumatic irAE in patients receiving these novel cancer therapies.
引用
- Abdel-Wahab N, Suarez-Almazor ME. Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy. Rheumatology (Oxford). 2019. PMID: 31816084. doi:10.1093/rheumatology/kez297
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。